• ORLADEYO® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older. One capsule of ORLADEYO per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein.
  • KYBORA helped identify the opportunity for Pint Pharma, established contact with BioCryst, helped build the business case and helped negotiate the final agreement for Pint Pharma.
  • Agreement further reinforces Pint Pharma’s ability to effectively file and commercialize innovative therapies in Latin America.
  • https://ir.biocryst.com/news-releases/news-release-details/biocryst-selects-pint-pharma-commercial-partner-orladeyor

About the author.


20 years of experience in international business development in the pharmaceutical industry. Head of commercial operations and business development for Bristol-Myers Squibb in 16 Latin American countries. Global management consultant. Speaks French and Spanish fluently. Completed nine transactions in global markets in the past three years.

No Comments. Leave a comment  

Leave a Reply

Your email address will not be published. Required fields are marked *